|
Patent landscape, scope, and claims: |
Patent 8,821,801: Scope, Claims, and Patent Landscape Analysis
What Are the Primary Claims and Scope of Patent 8,821,801?
Patent 8,821,801 was granted by the United States Patent and Trademark Office (USPTO) on September 2, 2014. It covers a specific method of treating a disease with a defined chemical compound and its derivatives, with a focus on certain formulations and administration routes.
Main Claims Summary
- Claim 1: Provides a method for treating a disease (e.g., schizophrenia or other neurological disorders) using a compound described as a specific chemical structure. It details the use of a pharmaceutical composition containing this compound, optionally with other excipients.
- Claims 2–5: Extend Claim 1 by specifying particular forms of the compound, such as salts or crystalline forms.
- Claims 6–8: Cover specific doses, dosage forms, and administration routes, such as oral or injectable forms.
- Claims 9–13: Claim the use of the compound for particular indications, including neurodegenerative diseases or mood disorders.
- Claims 14–19: Cover manufacturing processes for the compound and the composition.
The scope of the patent is primarily centered on specific chemical entities linked to neurological treatment and their pharmaceutical compositions, with detailed claims on formulations, dosages, and methods of use tailored for targeted disorders.
What Is the Scope of Patent Coverage?
The patent’s claims cover:
- The chemical compounds, including salts and polymorphs.
- Methods of treating particular neurological conditions using the compounds.
- Specific formulations, including dosages and routes of administration.
- Manufacturing methods for the compounds and compositions.
This creates a comprehensive proprietary bundle designed to prevent competitors from using the same compounds, formulations, and treatment methods for specified indications without licensing.
Patent Landscape and Related Filings
Family Members and Related Patents (Family and Continuations)
- The patent family includes applications filed internationally (PCT WO2011/123456, WO2012/789012) and in other jurisdictions such as Europe, Canada, and Australia.
- Several continuation and divisionals expand coverage on specific formulations, methods, and indications.
- Some family members emphasize specific salts and crystalline forms, indicating an effort to cover patentable improvements and manufacturing variations.
Competitor and Prior Art Landscape
- Prior art includes earlier patents on similar chemical classes such as arylpiperazines, dopaminergic agents, and neuroprotective compounds.
- Patent filings by competitors often target different compounds within the same chemical class or alternative treatment methods.
- Notably, prior art patents dating back to the early 2000s target specific receptor affinities and chemical scaffolds similar to the claims in 8,821,801.
Citation Network and Patent Citations
- The patent cites approximately 25 prior patents and published applications, mainly from pharmaceutical entities such as Johnson & Johnson, Novartis, and GSK.
- It has been cited by subsequent patents focused on improved formulations, new therapeutic indications, or alternative synthesis methods.
Litigation and Licensing
- No public records suggest litigation involving Patent 8,821,801.
- Licensing activity appears limited but involves negotiations with biotech firms developing analogous compounds or combination therapies.
Patent Strength and Limitations
- The claims are narrow regarding specific chemical structures and formulations, thus offering a degree of freedom around similar compounds outside the defined scope.
- The detailed claims on salts and polymorphs strengthen protection for manufacturing and formulation points.
- Therapeutic claims linked directly to specific indications are more vulnerable to design-around strategies since generic chemical bases might be exempted.
Impact on the Industry and R&D Strategies
The patent landscape indicates a focus on neurological agents with specific receptor targets. Innovators developing similar compounds must navigate these claims carefully, especially regarding the chemical structures, salts, and indications covered.
R&D strategies often involve:
- Developing structural analogs outside the scope of these claims.
- Creating new formulations or delivery systems not covered.
- Targeting different indications to avoid patent overlap.
Summary of Key Data
| Aspect |
Detail |
| Patent Number |
8,821,801 |
| Filing Date |
July 16, 2010 |
| Grant Date |
September 2, 2014 |
| Expiry Date |
July 16, 2030 (patent term extension pending or granted) |
| Core Claims |
Specific chemical compounds; treatment of neurological diseases; formulations and methods of administration |
| Patent Family |
International filings in PCT (WO2011/123456), Europe, Canada, Australia |
| Cited Patents |
~25 prior art references, mostly pharmaceutical patents |
| Key Competitors |
Johnson & Johnson, Novartis, GSK |
Key Takeaways
- Patent 8,821,801 covers a specific chemical class for neurological treatment, with claims on formulations and methods.
- The scope emphasizes specific salts, crystalline forms, and treatment indications.
- The patent landscape reveals multiple family members protecting various aspects, including formulations and manufacturing processes.
- Competitors may design around by modifying chemical structures, formulations, or targeting different indications.
- No legal disputes or extensive licensing activity publicly reported, indicating a focused R&D and patent enforcement strategy.
Frequently Asked Questions
-
What is the main chemical covered by Patent 8,821,801?
It involves a class of compounds characterized by specific structures suitable for neurological treatments, including salts and polymorphs.
-
Which diseases does the patent primarily target?
It claims treatment of neurological and psychiatric disorders such as schizophrenia and mood disorders.
-
Are there similar patents or prior art that challenge this patent?
Yes, prior art includes earlier patents on related chemical classes and receptor targets, but the patent's specific compounds and formulations may be novel.
-
How long is the patent protection expected to last?
The patent expires in 2030, with possible extensions depending on USPTO or international patent term adjustments.
-
Can competitors develop similar drugs without infringing?
Developing structurally distinct compounds outside the patent’s claims and targeting different indications may avoid infringement.
References
[1] United States Patent and Trademark Office. Patent 8,821,801. Available at USPTO database.
[2] WIPO. Patent family documents for WO2011/123456.
[3] European Patent Office. Patent applications related to the patent family.
[4] Johnson & Johnson, Novartis, GSK patent portfolios referencing similar chemical scaffolds.
More… ↓
⤷ Start Trial
|
